Current molecular medicine · 2022
To Vaccinate or not to Vaccinate; That is the Question! (New Insights into COVID-19 Vaccination).
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
El-Nakeep Sarah
Аннотация
OBJECTIVE: This mini-review of literature aimed to discuss the obstacles and benefits of vaccination in the era of the current pandemic, either the COVID-19 vaccines, which are on their way to be released, or the influenza vaccines, regarding which much debate is ongoing concerning their effectiveness for ameliorating the severity of the COVID-19 pandemic.
METHODOLOGY: A literature search was done till November 2020 in the PubMed database.
RESULTS: Pathophysiology behind the COVID-19 vaccination, the related obstacles and future perspectives are discussed in detail. Discussion on influenza vaccination during the pandemic, along with the most recent guidelines, is also presented.
CONCLUSION: During the COVID-19 pandemic, influenza vaccination is mandatory for all individuals, provided that there are no contraindications. Three SARS-CoV-2 vaccines are being released till the time being, while FDA approval for monoclonal antibodies for the treatment of at-risk outpatients to lower hospitalization rates is ongoing.
METHODOLOGY: A literature search was done till November 2020 in the PubMed database.
RESULTS: Pathophysiology behind the COVID-19 vaccination, the related obstacles and future perspectives are discussed in detail. Discussion on influenza vaccination during the pandemic, along with the most recent guidelines, is also presented.
CONCLUSION: During the COVID-19 pandemic, influenza vaccination is mandatory for all individuals, provided that there are no contraindications. Three SARS-CoV-2 vaccines are being released till the time being, while FDA approval for monoclonal antibodies for the treatment of at-risk outpatients to lower hospitalization rates is ongoing.